Could Weight-Loss drugs slow aging in postmenopausal women?
NCT ID NCT07057310
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study investigates whether GLP-1 receptor agonists (semaglutide or tirzepatide), combined with diet and exercise, can improve physical function, reduce biological aging, and enhance vascular health in postmenopausal women with obesity. Participants will take the medication as prescribed and follow a lifestyle program. The goal is to see if weight loss from these drugs leads to better mobility, balance, and heart health, and whether it can slow age-related decline.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- semaglutide or tirzepatide (GLP-1 receptor agonists) plus lifestyle modification (diet and exercise)
- What this could lead to
- If successful, this could show that GLP-1 agonists not only reduce weight but also improve physical function and slow biological aging in postmenopausal women.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply broadly. Side effects of GLP-1 drugs include nausea and gastrointestinal issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENOPAUSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- A daily pill for obesity? zenagamtide faces its biggest test yet.
- Dance and walking may boost heart health in obesity — a trial puts it to the test